Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal conjugate vaccine ACWY
- Development stage
- Approved
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **meningococcal conjugate vaccine ACWY** is a quadrivalent bacterial vaccine indicated for active immunization to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W, and Y in children and adults. It works by inducing the body's immune system to produce antibodies against these serogroups, preventing serious infections like bacterial meningitis and sepsis. The vaccine contains purified capsular polysaccharides from each target group conjugated to a carrier protein (such as diphtheria or tetanus toxoid), enhancing immunogenicity. It does **not** protect against serogroup B and does not treat active infection. Its primary indications include routine immunization in adolescents, as well as use for people at increased risk (e.g., those with certain medical conditions, travelers to endemic regions, military recruits, and college freshmen in group housing)[1][2][3][4][6].
- Brand names
- MenactraMenveoMenQuadfi
- Other names
- meningococcal (groups A, C, Y, W) conjugate vaccineMenACWYquadrivalent meningococcal conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal conjugate vaccine ACWY.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal conjugate vaccine ACWY.